|
Apr 8
|
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
|
|
Apr 5
|
Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL)
|
|
Apr 5
|
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
|
|
Mar 29
|
Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL)
|
|
Mar 25
|
Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL)
|
|
Mar 22
|
Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth
|
|
Mar 19
|
Director Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL)
|
|
Mar 5
|
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
|
|
Feb 12
|
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors
|
|
Jan 8
|
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones
|
|
Jan 1
|
Nuvalent, Inc. (NASDAQ:NUVL) Shares Could Be 35% Below Their Intrinsic Value Estimate
|
|
Dec 22
|
Director Anna Protopapas Sells 5,000 Shares of Nuvalent Inc (NUVL)
|
|
Dec 21
|
Chief Development Officer Darlene Noci Sells 40,000 Shares of Nuvalent Inc (NUVL)
|
|
Dec 21
|
Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Sep 18
|
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
|
|
Sep 10
|
We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely
|